CAR T-cell innovation could pave the way for less toxic therapy for multiple myeloma

FDA approves Darzalex Faspro combination for MM

FDA has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomid, and dexamethasone (D-VRd) for induction and consolidation in patients with newly-diagnosed multiple myeloma who are eligible for an autologous stem cell transplant.

August 02, 2024

Vol.50 No.31

Clinical Roundup

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

A new study details the critical influence of CD5, a key immunomodulatory protein, on engineered T-cell therapies, which is the foundational basis of the clinical-stage cell therapy company Vittoria Biotherapeutics’ proprietary Senza5TM platform.

July 26, 2024

Vol.50 No.30

Drugs & Targets

EMA accepts MAA for GSK’s Blenrep combinations for R/R MM

The European Medicines Agency has accepted the marketing authorization application for Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BorDex) or pomalidomide plus dexamethasone (PomDex) as a treatment for relapsed or refractory multiple myeloma.

July 26, 2024

Vol.50 No.30

Conversation with The Cancer Letter

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.

July 12, 2024

Vol.50 No.28

By Matthew Bin Han Ong

Clinical Roundup

Elrexfio produces median OS of >2 two years in R/R MM in single-arm phase II study

The phase II MagnetisMM-3 study of Elrexfio (elranatamab-bcmm) in patients with heavily pretreated relapsed or refractory multiple myeloma demonstrated a median OS of 24.6 (95% CI, 13.4, NE) months in cohort A (n=123) of the pivotal single arm trial.

June 21, 2024

Vol.50 No.25

Drugs & Targets

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

Patients treated with CAR T-cell medicines should be monitored life-long for secondary malignancies.

June 21, 2024

Vol.50 No.25

CAR T-cell innovation could pave the way for less toxic therapy for multiple myeloma

YOU MAY BE INTERESTED IN

FDA approves Darzalex Faspro combination for MM

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

EMA accepts MAA for GSK’s Blenrep combinations for R/R MM

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

Elrexfio produces median OS of >2 two years in R/R MM in single-arm phase II study

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

Renew today!

Subscriber content

Login

CAR T-cell innovation could pave the way for less toxic therapy for multiple myeloma

YOU MAY BE INTERESTED IN

FDA approves Darzalex Faspro combination for MM

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

EMA accepts MAA for GSK’s Blenrep combinations for R/R MM

Infections are a major cause of death in patients treated with CAR T-cell therapyMeta-analysis focused on causes of death, excluding relapse, recurrence

Elrexfio produces median OS of >2 two years in R/R MM in single-arm phase II study

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

Login

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence